{'fraction_non_alphanumeric': 0.02029664324746292, 'fraction_numerical': 0.01483216237314598, 'mean_word_length': 4.800904977375565, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The action of streptodecase on the size of the focal lesion, the hemostatic system, blood rheology and microcirculation in relation to the time of the start of the treatment of patients with an acute myocardial infarct].

Fifty patients with myocardial infarction (MI) were given streptodecase intravenously (the main group). Depending on the time elapsed from the appearance of the disease symptoms and the onset of streptodecase injection, the main group was distributed into 2 subgroups (less than or equal to 4 h and 4 to 8 h). The size of myocardial injury was judged from the activity CPK and ECG mapping in 35 thoracic leads. The Size of MI in the main group was significantly less than in the control group. At the same time the 2 subgroups of the patients demonstrated no significant difference in myocardial injury. This is accounted for by the fact that the majority of the patients (75%) were given the thrombolytic between the 120th and 360th minute since the disease onset. In view of the fact that streptodecase was discovered to exert a lasting beneficial effect (10 to 14 days) on hemostasis, hemorheology and microcirculation, it is suggested that the drug be used at later times of MI to prevent and treat complications consequent on microcirculatory disorders.